EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
EG 427 has raised $28.2M in total funding. The most recent round was Series B. The last funding was announced in February 2025.
EG 427's investors include Bpifrance, Andera Partners, SCI Ventures, David Lamond, Stephane Boissel.
EG 427 is headquartered in Paris, France.
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
EG 427 is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EG 427 — Funding & Investors." VCBacked, February 20, 2025, https://www.vcbacked.co/company/eg-427. Accessed July 19, 2026.
VCBacked. (2025). EG 427 — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/eg-427
{{cite web |title=EG 427 — Funding & Investors |url=https://www.vcbacked.co/company/eg-427 |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated